On October 26, 2023, Shandong New Route Biotechnology Co., Ltd. ("New Route") announced further good news: the unveiling ceremony of the "Phage Industry Research Institute" was a complete success, signaling fresh momentum for New Route's development and an unstoppable growth trajectory.
Researcher Wang Ran, Deputy Director of the Jiangsu Academy of Agricultural Sciences, Dr. Sun Lichang, Associate Researcher, and leaders from various sectors attended the unveiling ceremony of the "Phage Industry Research Institute" and, together with the guests present, witnessed this moment of honor.
The Phage Industry Research Institute was jointly established by the Jiangsu Academy of Agricultural Sciences and Shandong New Route Biotechnology Co., Ltd. Backed by the Jiangsu Academy of Agricultural Sciences and the International Phage R&D Center, New Route has built a research team with more than 30 PhD and master's degree holders as its core backbone. The company has long focused on developing phage products as antibiotic alternatives, providing healthy development solutions for bacterial disease control across China's livestock, agriculture, and food industries. Under the leadership of Chairman Wang Guoqiang, New Route continues to achieve breakthroughs and is committed to providing customers with high-quality, innovative products for bacterial disease prevention and control. The successful unveiling ceremony marks another milestone in New Route's development in phage research, and the company will further strengthen cooperation with research institutions at home and abroad to actively advance in-depth phage research.
Bacteriophages, as viruses capable of attacking bacteria, hold broad application prospects in the field of biotechnology. Phage therapy, as an emerging alternative to antibiotics, is of great significance for solving the problem of antimicrobial resistance in animal-derived pathogens. Driven by antibiotic-restriction policies and environmental regulations, interest in phage R&D continues to rise, and the outlook for antibiotic reduction and replacement is broad. The future market size of phage therapy is mainly driven by three factors: (1) Significant efficacy: as a biological product that lyses bacteria, phage therapy is highly effective against drug-resistant bacterial infections; (2) Antibiotic replacement: phage therapy has clear advantages over antibiotic therapy and is expected to replace antibiotics as a new type of antibacterial agent, offering broad market potential; (3) Growing demand for human-use pharmaceuticals: the number of cancer patients in China continues to rise each year, with new cancer cases in China projected to exceed 5 million by 2022; growing demand for cancer and disease treatment is driving increased demand for anti-infective and antibacterial drugs.
The promotion and application of New Route's phage products has not only improved production standards in the livestock farming industry but also effectively reduced the use of antibiotics and disinfectants. It is estimated that, over the past three years, phage products have cumulatively helped the farming industry reduce antibiotic and disinfectant use by more than 100 tons, thereby improving farming efficiency and the safety of animal-derived food products.
The successful unveiling ceremony marks a solid step forward for New Route in technological innovation and the conversion of research achievements into practical applications, laying a solid foundation for the company's future development. Let us look forward together to "New Route" charting an unstoppable course ahead and achieving even greater success!
